** charts before earnings **
** charts after earnings **
Insys Therapeutics beats by $0.02, beats on revs :
- Reports Q3 (Sep) earnings of $0.07 per share, $0.02 better than the Capital IQ Consensus of $0.05; revenues fell 39.5% year/year to $55.18 mln vs the $54.17 mln Capital IQ Consensus.
- Gross margin was 92% for the third quarter of 2016 compared with 92% for the comparable quarter of 2015.
- The Company had $217.2 million in cash, cash equivalents, and short-term and long-term investments, no debt, and $269 million in stockholders' equity as of September 30, 2016.
- "Although Subsys volumes declined in the quarter, we are pleased to have maintained a mid-40% market share and believe the product will continue to provide a solid financial foundation for growth and to support our R&D efforts. We are currently awaiting DEA scheduling of Syndros, our recently FDA approved product for cancer induced nausea and vomiting and anorexia associated with weight loss in AIDS patients. We look forward to launching Syndros, our second commercial product, which we believe has distinct advantages over the current formulation of dronabinol in soft gel capsule. We remain excited about our pipeline and believe that both our spray and cannabinoid platform products will provide opportunities for future growth"
No comments:
Post a Comment